Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery
Technology in Cancer Research & Treatment · 2025
DOI: 10.1177/15330338251313945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, 2025. Verfasst von Veselin Popov und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, Bulgaria. Hauptthemen laut MEDLINE: Radiosurgery, Hypoxia-Inducible Factor 1, alpha Subunit, Brain Neoplasms, Angiopoietin-2. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
The contemporary concept of carcinogenesis summarizes the role of hypoxia, neoangiogenesis, and hemostasis, including in the stage of progression and metastasis of the tumor process. Metastatic disease is a serious therapeutic challenge for any oncological condition. The purpose of this study was to evaluate the dynamics of specific indicators of neoangiogenesis and hypoxia as potential biomarkers for therapeutic efficacy or risk of disease progression in patients with brain metastases (BM) undergoing robotic stereotactic radiosurgery.
Methods
Two groups of patients (lung cancer and other types of cancers) with oligometastatic disease and brain metastases were included. The patients (n=66) were treated with CyberKnife system. Human Angiopoietin-2, Hypoxia inducible factor 1 α (HIF-1α) and human Vascular Endothelial Growth Factor-А (VEGF-А) were measured in this prospective longitudinal study.
Results
Analysis of human Angiopoietin-2, HIF-1α, human VEGF-A in the post-treatment period showed a statistically significant decrease between the baseline and the 6 months post-treatment time point in both patient groups. The baseline value of serum VEGF-А in the group with lung cancer decreased by 40%, Аngiopoietin-2-by 48%, HIF-1α -by 43%. In the group with other types of cancers, VEGF-А decreased by 54.75%, Аngiopoietin-2-by 52%, HIF-1α -by 39.5%. Despite the significant reduction, the levels remained significantly higher in both groups than in healthy controls.
Conclusion
This study underscores the potential of integrating molecular markers like VEGF-A, Angiopoietin-2, and HIF-1α into clinical decision-making to enhance outcomes for patients with brain metastases undergoing RSRS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Medical University of Plovdiv, Plovdiv, Bulgaria.
- UMHAT "Sv. Georgi"- Plovdiv, Bulgaria.
ORCID-Profile: Veselin Popov
Zitieren
APA
Popov, V., Raycheva, G., & Grudeva-Popova, Z. (2025). Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338251313945
Vancouver
Popov V, Raycheva G, Grudeva-Popova Z. Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery. Technology in Cancer Research & Treatment. 2025. doi:10.1177/15330338251313945
BibTeX
@article{Popov2025,
author = {Popov, Veselin and Raycheva, Gabriela and Grudeva-Popova, Zhanet},
title = {Dynamics of VEGF-А, Аngiopoietin-2 and HIF-1α Levels in Patients with Brain Metastases Treated with Cyberknife Radiosurgery},
journal = {Technology in Cancer Research & Treatment},
year = {2025},
doi = {10.1177/15330338251313945}
}
EUVIMED